Across 56 European CTIS-authorized multiple sclerosis phase II/III trials, 38 trials listed CRO support, equal to 67.9%. IQVIA and ICON were the most active CRO groups, each supporting 16 of 56 trials (28.6%). CRO need was strongest when operational complexity increased: 28 of 28 trials with 4+ countries used CROs, and 29 of 35 trials with 10+ sites used CROs.
IQVIA and ICON were tied as the leading CRO groups, each appearing in 16 of 56 trials (28.6%). Syneos Health followed with 11 trials (19.6%), while Labcorp / Q² Solutions appeared in 10 trials (17.9%).
MS outsourcing is concentrated around large global CRO networks plus specialized service vendors. IQVIA and ICON are the strongest general CRO signals, while Labcorp / Q², Clario / ERT, Endpoint Clinical, NeuroRx and Neurostatus reflect the high need for central lab, eCOA, randomization, imaging and neurological rating infrastructure.
CRO need was most strongly linked to cross-border and site-network complexity. CRO support appeared in 28 of 28 trials with 4+ countries (100.0%) and 29 of 35 trials with 10+ sites (82.9%). Participant count alone was a weaker predictor: only 2 of 5 trials with 500+ participants listed CRO support.
| Capacity measure | Band | CRO use |
|---|---|---|
| Countries | 1 country | 6/22 · 27.3% |
| Countries | 2–3 countries | 4/6 · 66.7% |
| Countries | 4+ countries | 28/28 · 100.0% |
| Sites | 1–3 sites | 4/11 · 36.4% |
| Sites | 4–9 sites | 5/10 · 50.0% |
| Sites | 10+ sites | 29/35 · 82.9% |
| Planned sample size | 500+ planned | 12/16 · 75.0% |
| Recruitment window | 60+ months | 20/26 · 76.9% |
The operational threshold for CRO need is not simply “large enrollment.” It is multi-country CTIS execution, country-level Part II coordination, site activation, monitoring, local documents and vendor orchestration. The clearest CRO trigger is 4+ countries or 10+ sites.
CRO support was high in relapsing MS and progressive MS. Relapsing MS appeared in 26 trials, with 19 CRO-supported (73.1%). Progressive MS appeared in 18 trials, with 13 CRO-supported (72.2%). Primary progressive MS had the strongest CRO signal at 6 of 6 trials (100.0%).
Progressive MS and relapsing MS both create strong outsourced operating demand. Progressive programs often require broader neurological rating, imaging and longer follow-up support, while relapsing MS programs are frequently larger and more geographically distributed.
The most common outsourced functions were central laboratory, PK and biomarker services, present in 38 of 56 trials (67.9%). Imaging, EDSS or central reading appeared in 34 trials (60.7%), followed by eCOA, PRO, ECG, IxRS or randomization services in 31 trials (55.4%).
| Central laboratory / PK / biomarkers | 38/56 · 67.9% |
| Imaging / EDSS / central reading | 34/56 · 60.7% |
| eCOA / PRO / ECG / IxRS / randomization | 31/56 · 55.4% |
| IMP / ancillary supplies / logistics | 27/56 · 48.2% |
| Patient reimbursement / travel / home nursing | 20/56 · 35.7% |
| Data management / analysis / statistics | 19/56 · 33.9% |
| Monitoring / site management / CRO | 16/56 · 28.6% |
| Patient recruitment / retention | 7/56 · 12.5% |
MS trials outsource the functions that are hardest to standardize across EU sites: central labs, biomarker and PK testing, MRI or EDSS-style central review, electronic outcomes, randomization and patient logistics. This is especially relevant for CTIS submissions because each Member State adds local site, document and operational complexity.
The largest site networks were concentrated in Poland (218 sites), France (192), Spain (184), Italy (147) and Germany (141). Poland also led participant allocation with 2,593 participants, followed by France with 1,651 and Spain with 797.
For CRO targeting, the strongest CTIS geography signals are Poland, France, Spain, Italy and Germany. These countries combine high site density with recurring participation in CRO-supported trials, making them priority markets for EU submission, Part II coordination, site contracting, monitoring and patient logistics.
Commercial sponsors relied on CROs far more often than academic or hospital sponsors: 36 of 40 pharma-sponsored trials used CROs (90.0%), compared with 2 of 15 academic or hospital-sponsored trials (13.3%). CRO-supported trials also used digital or remote recruitment more often: 11 of 38 CRO-supported trials (28.9%) versus 2 of 18 non-CRO trials (11.1%).
The best CRO prospecting filter is not only disease area. The strongest commercial signals are pharma sponsorship, monoclonal antibody or mixed-modality programs, multi-country CTIS footprint, 10+ sites, longer recruitment windows and patient-facing recruitment or retention activity.
CTIS means Clinical Trials Information System. CRO means contract research organization. eCOA means electronic clinical outcome assessment. PRO means patient-reported outcome. IxRS means interactive response technology for randomization and supply assignment. EDSS means Expanded Disability Status Scale. IMP means investigational medicinal product.